Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:43 PM
Ignite Modification Date:
2025-12-24 @ 3:43 PM
NCT ID:
NCT00058292
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically confirmed B-cell non-Hodgkin's lymphoma
* Relapsed or refractory disease
* CD20-positive disease
* Must have received at least 1 prior treatment regimen
* Complete remission with prior conventional salvage chemotherapy is allowed
* No more than 25% lymphoma in bone marrow
* No circulating malignant cells on blood smear
* No CNS involvement by lymphoma
* No HIV- or AIDS-related lymphoma
PATIENT CHARACTERISTICS:
Age
* Over 17
Performance status
* ECOG 0-2
Life expectancy
* At least 3 months
Hematopoietic
* Platelet count at least 100,000/mm\^3
* Absolute neutrophil count at least 1,500/mm\^3
Hepatic
* Transaminases less than 2 times normal
Renal
* Creatinine clearance greater than 50 mL/min
Cardiovascular
* LVEF at least 45%
Pulmonary
* Corrected DLCO at least 70% of predicted
* FEV\_1 or FVC greater than 60%
Other
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* No active infection
* No serious nonmalignant disease or other condition that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
* More than 4 weeks since prior rituximab and recovered
* No other prior murine antibodies
* No prior stem cell transplantation
* No prior radioimmunoconjugate therapy
Chemotherapy
* See Disease Characteristics
* More than 6 weeks since prior nitrosoureas or mitomycin and recovered
Endocrine therapy
* No concurrent systemic corticosteroids
Radiotherapy
* Recovered from prior radiotherapy
* No prior external beam irradiation to more than 25% of the active bone marrow
Surgery
* More than 4 weeks since prior major surgery and recovered
Other
* More than 3 weeks since prior anticancer therapy
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
17 Years
Study:
NCT00058292
Study Brief:
Protocol Section:
NCT00058292